Therapy

Lamivudine Resistance Differs in HIV+ and HBV+

Published in Hepatitis Weekly, May 11th, 1998

Lamivudine resistance patterns differ among those given the agent for hepatitis B virus and those taking it for HIV infection.

Researchers found that resistance tends to develop much slower in hepatitis B virus (HBV) positive patients.

"In HIV-1, resistance to lamivudine is usually observed within a few weeks," Hubert G.M. Niesters and colleagues from The Netherlands' University Hospital Rotterdam wrote ("Identification of More Than One Mutation in the Hepatitis B Virus Polymerase Gene Arising During Prolonged Lamivudine Treatment," Journal of Infectious Diseases, May 1998;177:1382-1385).

"In our study and those of others on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-05-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry